Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Polycystic Ovary Syndrome 21Glioblastoma 5Endometrial Neoplasms 5Breast Neoplasms 5Neoplasms 4Squamous Cell Carcinoma of Head and Neck 3Prostatic Neoplasms 3Leukoplakia, Oral 3Insulin Resistance 3Ovarian Neoplasms 2Metabolic Syndrome 2Metabolic Diseases 2Medulloblastoma 2Infertility 2Erythroplasia 2Carcinoma, Non-Small-Cell Lung 2Carcinoma, Intraductal, Noninfiltrating 2Adenocarcinoma Of Esophagus 2Weight Loss 1Uterine Cervical Neoplasms 1Urothelial Cancer 1Thyroid Diseases 1TP53 Y220C Mutation 1Smoldering Multiple Myeloma 1Sarcoma 1Rectal Neoplasms 1Prostate Cancer Recurrent 1Prediabetic State 1Posterior Fossa Ependymal Tumor 1Pleural Effusion, Malignant 1

Interventions

Rosuvastatin Calcium 1Metformin 1Digoxin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Drug-drug Interaction,SHR3680 × Metformin × 1 year × Clear all
NCT04621669 2026-06-05

Drug-durg Interaction of SHR3680 With Digoxin, Rosuvastatin Calcium and Metformin Hydrochloride

Jiangsu HengRui Medicine Co., Ltd.

Phase 1 Completed
36 enrolled

Drug-drug Interaction,SHR3680

Data powered by HemOnc (CC BY 4.0) Colophon âš¡